GlassScriptPhysician profile
Clay T Watson
NPI 1912661307
$1,110.83
in general payments reported to CMS, 2019-2025
13 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18.53 · 2022: $231 · 2023: $225 · 2024: $168 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $861.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $262.45 | 2022-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $227.97 | 2021-2025 | Ingrezza |
| Abbvie INC. | $126.29 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $97.08 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $96.82 | 2022-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Alkermes, INC. | $60.14 | 2022-2025 | Aristada, Aristada Initio, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $48.71 | 2022-2025 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $48.29 | 2022 | |
| Axsome Therapeutics, INC. | $44.99 | 2023-2024 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $33.81 | 2024-2025 | Trintellix |
| Lundbeck LLC | $32.61 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $17.30 | 2025 | Fanapt, Hetlioz |
| Bioxcel Therapeutics, INC. | $14.37 | 2023 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Watson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.